Intrathecal Administration of Nusinersen in Pediatric SMA Patients with and without Spine Deformities: Experiences and Challenges over 3 Years in a Single Center

Abstract

Spinal muscular atrophy (SMA) is a rare neurodegenerative disease leading to progressive muscular atrophy, respiratory failure, and premature death. Secondary thorax and spine deformities are frequent. In July 2017, the antisense oligonucleotide nusinersen (Spinraza) was approved for the recurrent lifelong intrathecal treatment of SMA in Europe. Lumbar punctures are challenging especially in SMA patients with severe spine deformities and after spine surgery. In the light of alternative SMA therapies that are available or are expected to be available soon and which are administered orally or via one-time infusion, an appraisal of the established therapy is significant. Discussion about which therapy is the best for each individual patient will have to include not only the safety and efficacy of data but also the application form and its burden for the patient and the health care system. Therefore, we analyzed our 3-year experiences and challenges with 478 lumbar puncture procedures in 61 pediatric SMA patients with and without spine deformities or instrumentation.

Keywords

spinal muscular atrophy - nusinersen - intrathecal application - spine deformities - fluoroscopy

Publication History

Received: 27 April 2020

Accepted: 02 September 2020

Article published online:
04 December 2020

• References

• 1 Lefebvre S, Bürglen L, Reboullet S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80 (01) 155-165
• 2 Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza
• 3 Michelson D, Ciafaloni E, Ashwal S. et al. Evidence in focus: nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 91 (20) 923-933
• 4 Finkel RS, Mercuri E, Darras BT. ENDEAR Study Group. et al; Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377 (18) 1723-1732
• 5 Mercuri E, Darras BT, Chiriboga CA. CHERISH Study Group. et al; Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378 (07) 625-635
• 6 Al-Zaidy SA, Kolb SJ, Lowes L. et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis 2019; 6 (03) 307-317
• 7 Day JW, Chiriboga CA, Crawford TO. et al. AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): pivotal phase 3 study (STR1VE). Update 2019; P1: 6-058
• 8 Seabrook TJ, Baranello G, Servais L. et al. FIREFISH Part 1: 1-year results on motor function in infants with Type 1 spinal muscular atrophy (SMA) receiving risdiplam (RG7916). Can J Neurol Sci 2019; 46 (s1) S31-S31
• 9 Mercuri E, Baranello G, Kirschner J. et al. Sunfish part 1: 18-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with type 2 or 3 spinal muscular atrophy. Neuromuscul Disord 2019; 29: S208
• 10 Wurster CD, Winter B, Wollinsky K. et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. J Neurol 2019; 266 (01) 183-194
• 11 Nascene DR, Ozutemiz C, Estby H, McKinney AM, Rykken JB. Transforaminal lumbar puncture: an alternative technique in patients with challenging access. AJNR Am J Neuroradiol 2018; 39 (05) 986-991
• 12 Veerapandiyan A, Pal R, D'Ambrosio S. et al. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy. Neurology 2018; 91 (07) e620-e624
• 13 Ortiz CB, Kukreja KU, Lotze TE, Chau A. Ultrasound-guided cervical puncture for nusinersen administration in adolescents. Pediatr Radiol 2019; 49 (01) 136-140
• 14 Lakhotia A, Bhalla S, Doll E, Gump W. Use of Ommaya reservoir with a thoracic spinal catheter for intrathecal delivery of nusinersen in a patient with spinal muscular atrophy type 2. Neurology 2018; 90: 464
• 15 Strauss KA, Carson VJ, Brigatti KW. et al. Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy. J Pediatr Orthop 2018; 38 (10) e610-e617
• 16 Weaver JJ, Natarajan N, Shaw DWW. et al. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety. Pediatr Radiol 2018; 48 (03) 392-397
• 17 Cordts I, Lingor P, Friedrich B. et al. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disorder 2020; 13: 1756286419887616
• 18 Özütemiz C, Karachunski P. , R Nascene D. Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience. Diagn Interv Radiol 2020;
• 19 Kizina K, Stolte B, Totzeck A. et al. Clinical implication of dosimetry of computed tomography-and fluoroscopy-guided intrathecal therapy with nusinersen in adult patients with spinal muscular atrophy. Front Neurol 2019; 10: 1166
• 20 Mousa MA, Aria DJ, Schaefer CM. et al. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy. Pediatr Radiol 2018; 48 (12) 1797-1805
• 21 Flotats-Bastardas M, Linsler S, Zemlin M, Meyer S. Nusinersen administration via an intrathecal port in a 16-year-old spinal muscular atrophy patient with profound scoliosis. Pediatr Neurosurg 2020; 55 (01) 54-57
• 22 Labianca L, Weinstein SL. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion. J Pediatr Orthop B 2019; 28 (04) 393-396